Efficacy of epinastine hydrochloride ophthalmic solution in the patients with allergic conjunctivitis after treating with olopatadine hydrochloride ophthalmic solution.
- Conditions
- Allergic conjunctivitis
- Registration Number
- JPRN-UMIN000016271
- Lead Sponsor
- Mihara eye clinic, medical corporation houjinkai
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Not provided
1) Patients given immunotherapy (hyposensitization therapy, modulated therapy). 2) Patients with ocular pruritus and hyperemia caused by a disease other than allergic conjunctivitis which will influence drug evaluation. 3) Patients with a history of atopic keratoconjunctivitis, spring catarrh, giant papillary conjunctivitis, corneal herpes, recurrent corneal erosion caused by the frequent occurrence of corneal injury or dry eye. 4) Patients with surgical history in the internal eye (including laser therapy) within 90 days prior to initiation of the clinical research. 5) Patients with possibility taking medicines (including anti-allergic agent, immunosuppressive drugs and adrenal cortex steroid except eye drops) which affect the efficacy of study drug. However, the use of ophthalmic solutions of adrenal cortex steroid is admitted as needed if there is no improvement in symptoms. 6) Females who are or may be pregnant, or lactating 7) Patients with a history of hypersensitivity to study drug or test material. 8) Patients with severe complications (such as immediate hospitalized care is required) which are identified inappropriate for safety reason. 9) Patients who have any other reasons that causes the study doctor to deem a subject unsuitable for the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method